Literature DB >> 12145225

The economic cost of diabetes in Canada, 1998.

Keith G Dawson1, Daniel Gomes, Hertzel Gerstein, James F Blanchard, Kristijan H Kahler.   

Abstract

OBJECTIVE: In Canada, diabetes poses a significant health problem, and current estimates of its economic burden have not incorporated the total cost of the disease. The objective of this study was to quantify the direct medical- and mortality-related productivity cost of diabetes in Canada for 1998. RESEARCH DESIGN AND METHODS: Direct medical costs included hospital services, physician services, and medicines consumed by people with diabetes. These costs were based on a top-down costing methodology that allocated 1998 total medical expenditures to diabetes. The prevalence of diagnosed and undiagnosed diabetes and the relative risk of complications in people with diabetes were used to estimate the proportion of medical services that were consumed by people with diabetes. Mortality-related productivity losses were calculated using the human capital approach.
RESULTS: After varying the assumptions in a sensitivity analysis, the total economic burden (in U.S. dollars) of diabetes and its chronic complications in Canada for 1998 was likely to be between $4.76 and $5.23 billion. In those people just with diagnosed diabetes, the direct medical costs associated with diabetes care, before considering any complications, were $573 million. Of the costs associated with the complications of diabetes, cardiovascular disease was by far the greatest, at $637 million.
CONCLUSIONS: Cardiovascular disease was the major contributor to the direct costs of diabetes. The preventive management of diabetes should receive priority attention, and the prevention of cardiovascular disease in the patient with diabetes should become an imperative.

Entities:  

Mesh:

Year:  2002        PMID: 12145225     DOI: 10.2337/diacare.25.8.1303

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  30 in total

1.  Glycemic self-monitoring and insurance coverage.

Authors:  Michele Heisler
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Adiposity, physical fitness and incident diabetes: the physical activity longitudinal study.

Authors:  P T Katzmarzyk; C L Craig; L Gauvin
Journal:  Diabetologia       Date:  2007-01-13       Impact factor: 10.122

Review 4.  Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes mellitus.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-06-01

6.  The cost of diabetes in Canada over 10 years: applying attributable health care costs to a diabetes incidence prediction model.

Authors:  Anja Bilandzic; Laura Rosella
Journal:  Health Promot Chronic Dis Prev Can       Date:  2017-02       Impact factor: 3.240

Review 7.  The societal burden of osteoporosis.

Authors:  David J Becker; Meredith L Kilgore; Michael A Morrisey
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

8.  Willingness to pay for inhaled insulin: a contingent valuation approach.

Authors:  Hamid Sadri; Linda D MacKeigan; Lawrence A Leiter; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Evaluation of a toolkit to improve cardiovascular disease screening and treatment for people with type 2 diabetes: protocol for a cluster-randomized pragmatic trial.

Authors:  Baiju R Shah; Onil Bhattacharyya; Catherine Yu; Muhammad Mamdani; Janet A Parsons; Sharon E Straus; Merrick Zwarenstein
Journal:  Trials       Date:  2010-04-23       Impact factor: 2.279

Review 10.  Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.

Authors:  Stewart B Harris; Cynthia N Lank
Journal:  Can Fam Physician       Date:  2004-03       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.